CO2022009514A2 - Inhibidores de sarm1 - Google Patents
Inhibidores de sarm1Info
- Publication number
- CO2022009514A2 CO2022009514A2 CONC2022/0009514A CO2022009514A CO2022009514A2 CO 2022009514 A2 CO2022009514 A2 CO 2022009514A2 CO 2022009514 A CO2022009514 A CO 2022009514A CO 2022009514 A2 CO2022009514 A2 CO 2022009514A2
- Authority
- CO
- Colombia
- Prior art keywords
- sarm1
- sarm1 inhibitors
- inhibitors
- treating
- present disclosure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción proporciona compuestos y métodos útiles para inhibir SARM1 y/o tratar y/o prevenir la degeneración axonal.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062958178P | 2020-01-07 | 2020-01-07 | |
US202063065736P | 2020-08-14 | 2020-08-14 | |
PCT/US2021/012333 WO2021142006A1 (en) | 2020-01-07 | 2021-01-06 | Inhibitors of sarm1 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022009514A2 true CO2022009514A2 (es) | 2022-10-21 |
Family
ID=74505335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0009514A CO2022009514A2 (es) | 2020-01-07 | 2022-07-06 | Inhibidores de sarm1 |
Country Status (19)
Country | Link |
---|---|
US (1) | US20230008433A1 (es) |
EP (1) | EP4087838A1 (es) |
JP (1) | JP7490781B2 (es) |
KR (1) | KR20220164471A (es) |
CN (1) | CN115175900A (es) |
AU (2) | AU2021206651B2 (es) |
BR (1) | BR112022013388A2 (es) |
CA (1) | CA3163265A1 (es) |
CL (1) | CL2022001825A1 (es) |
CO (1) | CO2022009514A2 (es) |
CR (1) | CR20220375A (es) |
DO (1) | DOP2022000141A (es) |
EC (1) | ECSP22053394A (es) |
IL (1) | IL294507A (es) |
JO (1) | JOP20220167A1 (es) |
MX (1) | MX2022008395A (es) |
PE (1) | PE20230165A1 (es) |
TW (1) | TW202140437A (es) |
WO (1) | WO2021142006A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230339913A1 (en) | 2020-08-04 | 2023-10-26 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
TW202334117A (zh) | 2020-08-24 | 2023-09-01 | 美商達薩瑪治療公司 | Sarm1之抑制劑 |
WO2022060812A1 (en) * | 2020-09-16 | 2022-03-24 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
MX2024001322A (es) | 2021-07-28 | 2024-04-30 | Nura Bio Inc | Derivados de piridina sustituida como inhibidores de sarm1. |
WO2024125624A1 (en) * | 2022-12-15 | 2024-06-20 | Sironax Ltd. | Sarm1 modulators, preparations, and uses thereof |
WO2024158607A1 (en) | 2023-01-24 | 2024-08-02 | Disarm Therapeutics, Inc. | Substituted 1h-pyrazole-4-carboxamides as sarm1 inhibitors |
WO2024158775A1 (en) | 2023-01-24 | 2024-08-02 | Disarm Therapeutics, Inc. | Pyridazines as sarm1 inhibitors |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6787555B2 (en) | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
AU2003288956A1 (en) * | 2002-10-30 | 2004-06-07 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
CN1732164A (zh) * | 2002-10-30 | 2006-02-08 | 沃泰克斯药物股份有限公司 | 可用作rock及其他蛋白质激酶抑制剂的组合物 |
AU2003300099A1 (en) | 2003-01-02 | 2004-07-29 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-Beta |
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
DE602005020611D1 (de) * | 2004-04-28 | 2010-05-27 | Vertex Pharma | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen |
ZA200704971B (en) * | 2004-12-16 | 2008-09-25 | Vertex Pharma | Pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases |
MX2007007330A (es) | 2004-12-16 | 2007-10-04 | Vertex Pharma | Piridonas de utilidad como inhibidores de quinasas . |
EP2036905B1 (en) * | 2006-06-28 | 2012-12-12 | ASKA Pharmaceutical Co., Ltd. | Pyridylisoxazole derivative |
WO2008034600A1 (en) * | 2006-09-21 | 2008-03-27 | Novartis Ag | Pyrrole derivatives useful for the treatment of cytokine-mediated diseases |
EP2238134A2 (en) * | 2007-12-20 | 2010-10-13 | Novartis AG | Bis-thiazole derivatives, process for their preparation and their use as medicaments |
AR069798A1 (es) * | 2007-12-20 | 2010-02-17 | Novartis Ag | Derivados de 1, 3-tiazol, metodos para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de medicamentos para el tratamiento de enfermedades mediadas por la fosfatidilinositol 3-cinasa. |
WO2009086303A2 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
WO2010093849A2 (en) * | 2009-02-13 | 2010-08-19 | Amgen Inc. | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions |
RU2570907C2 (ru) * | 2013-10-21 | 2015-12-20 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа. |
WO2015112847A1 (en) * | 2014-01-24 | 2015-07-30 | Confluence Life Sciences, Inc. | Arylpyridinone itk inhibitors for treating inflammation and cancer |
CN107835637A (zh) * | 2015-05-18 | 2018-03-23 | 转化药物开发有限责任公司 | 作为激酶抑制剂的杂环化合物 |
US11253503B2 (en) | 2016-09-24 | 2022-02-22 | Washington University | Inhibitors of SARM1 NADase activity and uses thereof |
US20180251431A1 (en) * | 2016-12-09 | 2018-09-06 | Vertex Pharmaceuticals Incorporated | 1,3-substituted pyrazole compounds useful for reduction of very long chain fatty acid levels |
MA52812A (fr) * | 2018-06-07 | 2021-04-14 | Disarm Therapeutics Inc | Inhibiteurs de sarm1 |
CN111253333A (zh) * | 2018-11-30 | 2020-06-09 | 青岛清原化合物有限公司 | N-(1,3,4-噁二唑-2-基)芳基甲酰胺类或其盐、制备方法、除草组合物和应用 |
US20230339913A1 (en) * | 2020-08-04 | 2023-10-26 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
-
2021
- 2021-01-06 PE PE2022001414A patent/PE20230165A1/es unknown
- 2021-01-06 WO PCT/US2021/012333 patent/WO2021142006A1/en active Application Filing
- 2021-01-06 TW TW110100350A patent/TW202140437A/zh unknown
- 2021-01-06 CN CN202180019643.9A patent/CN115175900A/zh active Pending
- 2021-01-06 JO JOP/2022/0167A patent/JOP20220167A1/ar unknown
- 2021-01-06 IL IL294507A patent/IL294507A/en unknown
- 2021-01-06 MX MX2022008395A patent/MX2022008395A/es unknown
- 2021-01-06 JP JP2022541796A patent/JP7490781B2/ja active Active
- 2021-01-06 BR BR112022013388A patent/BR112022013388A2/pt unknown
- 2021-01-06 KR KR1020227027204A patent/KR20220164471A/ko unknown
- 2021-01-06 CR CR20220375A patent/CR20220375A/es unknown
- 2021-01-06 AU AU2021206651A patent/AU2021206651B2/en active Active
- 2021-01-06 CA CA3163265A patent/CA3163265A1/en active Pending
- 2021-01-06 EP EP21703092.3A patent/EP4087838A1/en active Pending
- 2021-08-17 US US17/404,523 patent/US20230008433A1/en active Pending
-
2022
- 2022-07-05 CL CL2022001825A patent/CL2022001825A1/es unknown
- 2022-07-05 DO DO2022000141A patent/DOP2022000141A/es unknown
- 2022-07-06 CO CONC2022/0009514A patent/CO2022009514A2/es unknown
- 2022-07-07 EC ECSENADI202253394A patent/ECSP22053394A/es unknown
-
2024
- 2024-02-06 AU AU2024200703A patent/AU2024200703A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023510743A (ja) | 2023-03-15 |
IL294507A (en) | 2022-09-01 |
AU2021206651A1 (en) | 2022-07-14 |
CA3163265A1 (en) | 2021-07-15 |
JP7490781B2 (ja) | 2024-05-27 |
CL2022001825A1 (es) | 2023-06-02 |
CR20220375A (es) | 2022-09-22 |
MX2022008395A (es) | 2022-09-26 |
DOP2022000141A (es) | 2022-10-16 |
BR112022013388A2 (pt) | 2022-09-20 |
KR20220164471A (ko) | 2022-12-13 |
AU2024200703A1 (en) | 2024-02-29 |
WO2021142006A1 (en) | 2021-07-15 |
AU2021206651B2 (en) | 2024-02-22 |
EP4087838A1 (en) | 2022-11-16 |
ECSP22053394A (es) | 2022-11-30 |
JOP20220167A1 (ar) | 2023-01-30 |
PE20230165A1 (es) | 2023-02-01 |
CN115175900A (zh) | 2022-10-11 |
TW202140437A (zh) | 2021-11-01 |
US20230008433A1 (en) | 2023-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP22053394A (es) | Inhibidores de sarm1 | |
ECSP23012981A (es) | Inhibidores de sarm1 | |
PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
WO2020252229A3 (en) | Inhibitors of sarm1 | |
BR112018017086A2 (pt) | derivados de pirrolidina espiro-condensada como inibidores de enzimas desubiquitilantes (dub) | |
MX2021003819A (es) | Moduladores de alfa-1 antitripsina. | |
CO2024009571A2 (es) | Inhibidores de parp1 | |
EA201591278A1 (ru) | Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы | |
MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
MX2021001550A (es) | Inhibidores de transglutaminasa 2 (tg2). | |
WO2018195110A8 (en) | Regulation of ran translation by pkr and eif2a-p pathways | |
MX2023011608A (es) | Metodos para inhibir ras. | |
PE20210109A1 (es) | Moduladores de la expresion de irf4 | |
ECSP20082339A (es) | Moduladores de la expresión de apol1 | |
MX2018003301A (es) | Inhibidores de pcna. | |
BR112018068027A2 (pt) | método para tratar câncer em um paciente e composição farmacêutica | |
CL2021001246A1 (es) | Moduladores de expresión irf5. | |
CO2022000270A2 (es) | Inhibidores de enzimas | |
BR112024001180A2 (pt) | Composições e métodos para tratamento do melanoma | |
UY38352A (es) | Inhibidores de integrina alfavbeta6 | |
BR112022005895A2 (pt) | Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2 | |
UY38472A (es) | Moduladores de la expresión de foxp3 | |
BR112022010278A2 (pt) | Terapia combinada que envolve compostos macrocíclicos de diarila | |
CO2019001402A2 (es) | Método para prevenir o tratar la pérdida de la audición |